/

Società

As

Non verificato

AstraZeneca

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

135 comunicati stampa

Guarda tutti i comunicati

28/10/2026

AstraZeneca and Mark-Paul Gosselaar Launch Meet Your Mark to Raise Awareness of Cancer Biomarker Testing

Fonte

Emittente

1.00

0

25/10/2026

Scienza

Biotecnologia

Farmaceutica

Oncologia

Sanità

Salute

Medicina - Varie

Industria

Sonesitatug vedotin reduced the risk of death by 42% in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers in CLARITY-Gastric01

Fonte

Emittente

1.00

0

25/10/2026

Scienza

Biotecnologia

Farmaceutica

Oncologia

Salute

Igiene alimentare

Medicina - Varie

Eventi

Industria

TAGRISSO® (osimertinib) plus savolitinib reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO

Fonte

Emittente

1.00

0

24/10/2026

Scienza

Biotecnologia

Farmaceutica

Oncologia

Sanità

Salute

Medicina - Varie

Industria

IMFINZI® (durvalumab) plus tarlatamab-dlle reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trial

Fonte

Emittente

1.00

0

24/10/2026

Oncologia

Salute

Medicina - Varie

Scienza

Farmaceutica

Biotecnologia

Eventi

Fiere

Industria

Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer

Fonte

Emittente

1.00

0

22/10/2026

Oncologia

Salute

Igiene alimentare

Sanità

Medicina - Varie

Farmaceutica

Biotecnologia

Industria

ZEGFROVY® (sunvozertinib) now available in the US for patients with previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations

Fonte

Emittente

1.00

0

20/10/2026

Scienza

Medicina - Varie

Biotecnologia

Sanità

Salute

Farmaceutica

Industria

TEZSPIRE positive results from Phase III CROSSING trial in eosinophilic esophagitis including symptom improvement, histologic and endoscopic remission presented at United European Gastroenterology Week

Fonte

Emittente

1.00

0

19/10/2026

Oncologia

Salute

Medicina - Varie

Scienza

Farmaceutica

Biotecnologia

Eventi

Industria

AstraZeneca to present overall survival data from four pivotal Phase III trials in Presidential Symposia at ESMO 2026 featuring Sone-Ve, IMFINZI® (durvalumab), TAGRISSO® (osimertinib) and savolitinib

Fonte

Emittente

1.00

0

05/10/2026

AstraZeneca opens new global strategic R&D center in Kendall Square, Cambridge, Massachusetts

Fonte

Emittente

1.00

0

25/09/2026

Industria

Scienza

Igiene alimentare

Medicina - Varie

Biotecnologia

Salute

Farmaceutica

Sanità

Oncologia

Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin granted Priority Review in the US for patients with muscle-invasive bladder cancer

Fonte

Emittente

1.00

0

Seguaci

0

Compatibilità

0